Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification
American Journal of Hematology · 2023
DOI: 10.1002/ajh.26799 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Wan-Hsuan Lee und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
The 2022 International Consensus Classification (ICC) recategorized myeloid neoplasms based on recent advances in the understanding of the biology of hematologic malignancies, in which myelodysplastic syndrome (MDS) with blasts of 10%–19% is classified as MDS/acute myeloid leukemia (AML), MDS with mutated SF3B1 , irrespective of the number of ring sideroblasts, as MDS‐ SF3B1 , and those with multi‐hit TP53 mutations as MDS with mutated TP53 . In the analysis of 716 patients with MDS diagnosed according to the 2016 WHO classification, we found that 75.3% of patients remained in the MDS group based on the ICC, while 24.7% of patients were reclassified to the MDS/AML group after the exclusion of 15 patients who were classified to the AML group. Patients with MDS/AML showed a distinct mutational landscape and had poorer outcomes, compared to those with MDS. In the MDS group, patients with MDS‐ SF3B1 had higher frequencies of DNMT3A and TET2 mutations than those with MDS, not otherwise specified, with single lineage dysplasia or multilineage dysplasia. Patients with mutated TP53 were associated with dismal outcomes, irrespective of the blast percentage. In conclusion, this study showed that the ICC facilitates efficient segregation and risk‐stratification of MDS which can help guide the treatment choice of patients with the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu, Taiwan.
- Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Medical Education and Research, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.
ORCID-Profile: Wan-Hsuan Lee, Feng-Ming Tien, Min-Yen Lo, Yuan-Yeh Kuo, Hsin-An Hou
Zitieren
APA
Lee, W. H., Lin, C. C., Tsai, C. H., Tien, F. M., Lo, M. Y., Ni, S. C., Yao, M., Tseng, M. H., Kuo, Y. Y., Liu, M. C., Tang, J. L., Sun, H. I., Chuang, Y. K., Chou, W. C., Hou, H. A., & Tien, H. F. (2023). Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification. American Journal of Hematology. https://doi.org/10.1002/ajh.26799
Vancouver
Lee WH, Lin CC, Tsai CH, Tien FM, Lo MY, Ni SC, et al. Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification. American Journal of Hematology. 2023. doi:10.1002/ajh.26799
BibTeX
@article{Lee2023,
author = {Lee, Wan-Hsuan and Lin, Chien-Chin and Tsai, Cheng-Hong and Tien, Feng-Ming and Lo, Min-Yen and Ni, Sao-Chih and Yao, Ming and Tseng, Mei-Hsuan and Kuo, Yuan-Yeh and Liu, Ming-Chih and Tang, Jih-Luh and Sun, Hsun-I and Chuang, Yi-Kuang and Chou, Wen-Chien and Hou, Hsin-An and Tien, Hwei-Fang},
title = {Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification},
journal = {American Journal of Hematology},
year = {2023},
doi = {10.1002/ajh.26799}
}
EUVIMED